Literature DB >> 8190698

One-year treatment of non-diabetic and streptozotocin-diabetic rats with vanadyl sulphate did not alter blood pressure or haematological indices.

S Dai1, J H McNeill.   

Abstract

Circulatory and haematological effects of chronic administration of vanadyl sulphate in drinking water for one year in non-diabetic and streptozotocin-diabetic rats were investigated. At various time points during the treatment period and at 13 weeks following its withdrawal, systolic blood pressure and pulse rate were measured using a tail-cuff method and some selected haematological indices, including haematocrit, haemoglobin, erythrocyte count, reticulocyte percentage, leukocyte count, platelet count, and leukocyte composition of the peripheral blood were determined using standard methods. It was found that prolonged treatment of either nondiabetic or streptozotocin-diabetic rats with vanadyl sulphate did not cause significant changes in the parameters observed but significantly alleviated the occurrence of bradycardia and the decreased leukocyte count in the peripheral blood in streptozotocin-diabetic animals. No significant changes in systolic blood pressure, pulse rate, or haematological indices were observed following the withdrawal of vanadyl sulphate, except that the previously vanadyl-treated diabetic rats were found to have higher leukocyte count, platelet count and neutrophil percentage, and lower lymphocyte percentage in their leukocyte composition. It is concluded that vanadyl sulphate does not have a hypertensive effect nor is it significantly toxic to the haemopoietic system in rats.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8190698     DOI: 10.1111/j.1600-0773.1994.tb01084.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  8 in total

1.  Vanadium and diabetes. What about vanadium toxicity?

Authors:  J L Domingo
Journal:  Mol Cell Biochem       Date:  2000-01       Impact factor: 3.396

2.  Vanadium and diabetes. What about vanadium toxicity?: A reply.

Authors:  J H McNeill
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

Review 3.  Increased potency of vanadium using organic ligands.

Authors:  J H McNeill; V G Yuen; S Dai; C Orvig
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

4.  Anti-diabetic effects of a series of vanadium dipicolinate complexes in rats with streptozotocin-induced diabetes.

Authors:  Gail R Willsky; Lai-Har Chi; Michael Godzala; Paul J Kostyniak; Jason J Smee; Alejandro M Trujillo; Josephine A Alfano; Wenjin Ding; Zihua Hu; Debbie C Crans
Journal:  Coord Chem Rev       Date:  2011-10       Impact factor: 22.315

5.  New vanadium-based magnetic resonance imaging probes: clinical potential for early detection of cancer.

Authors:  Devkumar Mustafi; Bo Peng; Sean Foxley; Marvin W Makinen; Gregory S Karczmar; Marta Zamora; John Ejnik; Heather Martin
Journal:  J Biol Inorg Chem       Date:  2009-07-02       Impact factor: 3.358

6.  Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus.

Authors:  N Cohen; M Halberstam; P Shlimovich; C J Chang; H Shamoon; L Rossetti
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

Review 7.  Vanadium inhalation in a mouse model for the understanding of air-suspended particle systemic repercussion.

Authors:  T I Fortoul; V Rodriguez-Lara; A Gonzalez-Villalva; M Rojas-Lemus; G Cano-Gutierrez; M Ustarroz-Cano; L Colin-Barenque; L F Montaño; I García-Pelez; P Bizarro-Nevares; N Lopez-Valdez; C I Falcon-Rodriguez; R S Jimenez-Martínez; M L Ruiz-Guerrero; L S López-Zepeda; A Morales-Rivero; A Muñiz-Rivera-Cambas
Journal:  J Biomed Biotechnol       Date:  2011-05-22

8.  Quantitative Assessment of Proliferative Effects of Oral Vanadium on Pancreatic Islet Volumes and Beta Cell Numbers of Diabetic Rats.

Authors:  Leila Pirmoradi; Ali Noorafshan; Akbar Safaee; Gholam Abbas Dehghani
Journal:  Iran Biomed J       Date:  2015-10-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.